AZN vs. ORCL: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AZN and ORCL, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
AZN trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, ORCL is a standard domestic listing.
| Symbol | AZN | ORCL |
|---|---|---|
| Company Name | AstraZeneca PLC | Oracle Corporation |
| Country | United Kingdom | United States |
| GICS Sector | Health Care | Information Technology |
| GICS Industry | Pharmaceuticals | Software |
| Market Capitalization | 265.62 billion USD | 822.82 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | May 12, 1993 | March 12, 1986 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of AZN and ORCL by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | AZN | ORCL |
|---|---|---|
| 5-Day Price Return | 2.77% | -0.05% |
| 13-Week Price Return | 23.60% | 22.40% |
| 26-Week Price Return | 12.18% | 110.33% |
| 52-Week Price Return | 8.58% | 69.81% |
| Month-to-Date Return | 14.29% | 2.63% |
| Year-to-Date Return | 22.09% | 73.21% |
| 10-Day Avg. Volume | 1.68M | 23.30M |
| 3-Month Avg. Volume | 1.20M | 19.31M |
| 3-Month Volatility | 31.04% | 81.79% |
| Beta | 1.23 | 1.65 |
Profitability
Return on Equity (TTM)
AZN
19.84%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
AZN’s Return on Equity of 19.84% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
ORCL
66.28%
Software Industry
- Max
- 66.28%
- Q3
- 21.28%
- Median
- 9.33%
- Q1
- -8.77%
- Min
- -48.16%
In the upper quartile for the Software industry, ORCL’s Return on Equity of 66.28% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
AZN
14.68%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
AZN’s Net Profit Margin of 14.68% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
ORCL
21.08%
Software Industry
- Max
- 51.92%
- Q3
- 19.23%
- Median
- 6.98%
- Q1
- -7.14%
- Min
- -41.00%
A Net Profit Margin of 21.08% places ORCL in the upper quartile for the Software industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
AZN
20.04%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
AZN’s Operating Profit Margin of 20.04% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
ORCL
30.44%
Software Industry
- Max
- 60.40%
- Q3
- 21.25%
- Median
- 9.90%
- Q1
- -4.97%
- Min
- -43.50%
An Operating Profit Margin of 30.44% places ORCL in the upper quartile for the Software industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | AZN | ORCL |
|---|---|---|
| Return on Equity (TTM) | 19.84% | 66.28% |
| Return on Assets (TTM) | 7.76% | 7.56% |
| Net Profit Margin (TTM) | 14.68% | 21.08% |
| Operating Profit Margin (TTM) | 20.04% | 30.44% |
| Gross Profit Margin (TTM) | 82.07% | 69.66% |
Financial Strength
Current Ratio (MRQ)
AZN
0.86
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
AZN’s Current Ratio of 0.86 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
ORCL
0.62
Software Industry
- Max
- 4.29
- Q3
- 2.37
- Median
- 1.40
- Q1
- 1.03
- Min
- 0.25
ORCL’s Current Ratio of 0.62 falls into the lower quartile for the Software industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
AZN
0.73
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
AZN’s Debt-to-Equity Ratio of 0.73 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
ORCL
3.78
Software Industry
- Max
- 2.16
- Q3
- 0.86
- Median
- 0.31
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 3.78, ORCL operates with exceptionally high leverage compared to the Software industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
AZN
9.51
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
AZN’s Interest Coverage Ratio of 9.51 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
ORCL
4.92
Software Industry
- Max
- 89.65
- Q3
- 32.64
- Median
- 1.00
- Q1
- -9.84
- Min
- -71.23
ORCL’s Interest Coverage Ratio of 4.92 is positioned comfortably within the norm for the Software industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | AZN | ORCL |
|---|---|---|
| Current Ratio (MRQ) | 0.86 | 0.62 |
| Quick Ratio (MRQ) | 0.67 | 0.50 |
| Debt-to-Equity Ratio (MRQ) | 0.73 | 3.78 |
| Interest Coverage Ratio (TTM) | 9.51 | 4.92 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
AZN
1.86%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
AZN’s Dividend Yield of 1.86% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
ORCL
0.62%
Software Industry
- Max
- 0.22%
- Q3
- 0.11%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ORCL’s Dividend Yield of 0.62% is exceptionally high, placing it well above the typical range for the Software industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
Dividend Payout Ratio (TTM)
AZN
59.51%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
AZN’s Dividend Payout Ratio of 59.51% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
ORCL
40.62%
Software Industry
- Max
- 3.29%
- Q3
- 2.41%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 40.62%, ORCL’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Software industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
Dividend at a Glance
| Symbol | AZN | ORCL |
|---|---|---|
| Dividend Yield (TTM) | 1.86% | 0.62% |
| Dividend Payout Ratio (TTM) | 59.51% | 40.62% |
Valuation
Price-to-Earnings Ratio (TTM)
AZN
32.06
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
A P/E Ratio of 32.06 places AZN in the upper quartile for the Pharmaceuticals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
ORCL
65.29
Software Industry
- Max
- 145.74
- Q3
- 94.88
- Median
- 45.35
- Q1
- 26.66
- Min
- 8.80
ORCL’s P/E Ratio of 65.29 is within the middle range for the Software industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
AZN
4.71
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
AZN’s P/S Ratio of 4.71 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
ORCL
13.76
Software Industry
- Max
- 25.67
- Q3
- 13.68
- Median
- 8.28
- Q1
- 4.95
- Min
- 0.90
ORCL’s P/S Ratio of 13.76 is in the upper echelon for the Software industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
AZN
4.71
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
AZN’s P/B Ratio of 4.71 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
ORCL
26.30
Software Industry
- Max
- 30.67
- Q3
- 14.92
- Median
- 8.52
- Q1
- 3.89
- Min
- 0.38
ORCL’s P/B Ratio of 26.30 is in the upper tier for the Software industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | AZN | ORCL |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 32.06 | 65.29 |
| Price-to-Sales Ratio (TTM) | 4.71 | 13.76 |
| Price-to-Book Ratio (MRQ) | 4.71 | 26.30 |
| Price-to-Free Cash Flow Ratio (TTM) | 32.49 | 95.82 |